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Background:Heart failure (HF) is predominantly a disease of the elderly. Reliable risk stratiﬁcation would help in
the management of this population, but no model has been well evaluated in elderly HF patients in both acute
and chronic settings and not being restricted by ejection fraction. To evaluate the utility of the SENIORS risk
model, developed from a clinical trial of elderly patients with chronic HF, in an independent cohort (National
Spanish Registry: RICA) of elderly acute HF patients.
Methods:We applied the SENIORS riskmodel to 926 patients in RICA to estimate risk at one year of a) composite
outcome of all-cause mortality or cardiovascular hospital admission and b) all-cause mortality.
Results: In the RICA registry mean age was 78 years, mean ejection fraction 51% and 87% were in NYHA II and III.
At one year death/CV hospitalization occurred in 31.9% and all-causemortality in 19.5%. The riskmodel provided
good separation of Kaplan Meier curves stratiﬁed by tertile for death/CV hospitalization and all-cause mortality.
The observed versus expected rates of death/CV hospitalization in the lowest, middle and highest risk tertiles
were (%) 34/24, 45/41 and 57/67, and for death 13/16, 32/38 and 44/70 respectively. C-statistic for all-causemor-
tality or CV hospitalization was 0.60 and for all-cause mortality 0.66.
Conclusion: The SENIORS risk model was a reliable tool for relative risk stratiﬁcation among acute heart failure
patients in a “real world” registry, but predicted versus observed risk showed some variability. The model pro-
vides a useful basis for clinical risk prediction.© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Heart failure (HF) is a growinghealthcare problem, particularly in el-
derly patients. Despite of modern treatments, many patients require
frequent readmissions [1–3], which itself is a marker of poor prognosis.
Several HF risk models have been developed and validated using data
from observational studies and clinical trials, but these have mostly in-
cluded patients younger than 70 years and mainly with systolic dys-
function [4–12]. Since HF is a syndrome predominantly of the elderly,
it is important to have reliable risk stratiﬁcation tools speciﬁcally forz-Barquero).
land Ltd. This is an open access articlthis population. We previously developed a risk model from the
SENIORS dataset, based on widely available clinical and laboratory var-
iables, to predict prognosis in HF outpatients N70 years [13]. As patients
from clinical trials might not represent those from the “real world”with
numerous co-morbidities we applied the SENIORS risk model to RICA
(Registro Nacional de Insuﬁciencia Cardiaca) a prospective multi-
centre observational registry of elderly acute HF admissions. We
explored the utility of the model to stratify patients and to predict risk.
2. Methods
The RICA registry is a multi-centre, prospective, cohort study, coordinated by the
Working Group of Heart Failure of the Spanish Society of Internal Medicine [14,15]. This
registry includes data from public and private hospitals in Spain, and was approved bye under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Baseline characteristics of RICA and SENIORS patients included in the analysis.
Variable RICA (N 926) SENIORS
(N 1400)
p value
Demographic
Age (years ± SD) 77.7 ± 9.0 76.1 ± 4.7 b0.001
Gender (Female) % 52.5 37.1 b0.001
Medical history (%)
Hypertension 85.7 62.7 b0.001
Diabetes 47.4 26.9 b0.001
Prior myocardial infarction 20..6 43.9 b0.001
Atrial ﬁbrillation 54.3 34.9 b0.001
Hyperlipidaemia 47.3 45.7 0.50
Chronic obstructive pulmonary disease 27.3 7.1 b0.001
Peripheral arterial disease 14.4 5.1 b0.001
Clinical characteristics (%)
NYHA class b0.001
I 8.8 2.8
II 53.7 56.5
III 34.2 38.6
IV 3.3 2.1
Body mass index (kg/m2) 29.2 ± 6.4 26.7 ± 4.0 b0.001
Systolic blood pressure (mm Hg) 141.8 ± 29.3 139.5 ± 20.3 0.025
Diastolic blood pressure (mm Hg) 77.8 ± 17.2 80.7 ± 11.0 b0.001
Heart rate (beats/min) 90.3 ± 24.5 79.4 ± 13.9 b0.001
Laboratory
Haemoglobin (g/dL) 12.2 ± 2.1 13.8 ± 1.5 b0.001
Creatinine (μmol/L) 117.2 ± 59.0 102.1 ± 33.6 b0.001
MDRD (ML/min/1.73 m2) 58.3 ± 26.0 65.0 ± 19.6 b0.001
Sodium (mmol/L) 139.3 ± 4.8 141.6 ± 3.8 b0.001
Uric acid (μmol/L) 461.4 ± 139.4 395.7 ± 120.2 b0.001
Echo and ECG data
Left bundle branch block % 19.9 19.8 0.960
Right bundle branch block % 11.8 9.3 0.053
Left ventricular hypertrophy % 27.0 12.1 b0.001
Ejection fraction (%) 50.9 ± 15.1 35.7 ± 12.0 b0.001
Left atrial dimension (cm) 4.7 ± 0.9 4.4 ± 0.8 b0.001
Medications (%)
Beta Blocker 64.1 48.6 b0.001
ACE inhibitors 55.3 83.4 b0.001
Angiotensin receptors blockers 32.1 7.9 b0.001
Diuretics 89.2 83.4 b0.001
Spironolactone 32.5 27.6 0.011
Digoxin 26.2 41.4 b0.001
Calcium channel-blocker 21.8 13.4 b0.001
Statin 44.4 22.5 b0.001
Vitamin K antagonists 55.2 23.4 b0.001
Anti-arrhythmics 8.2 16.5 b0.001
End points at 1-year (%)
Mortality or cardiovascular
hospitalization
31.9 22.5 b0.001
Mortality 19.5 9.9 b0.001
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to January 2013, 1368 patients were enrolled in RICA from 52 centres. All patients consec-
utively admitted to the Internal Medicine units with acute decompensated HF, and cared
for by physicians participating in the registry (and with at least one year follow-up), were
included in this study. In addition to giving their informed consent, patients were recruit-
ed if they were≥50 years old with HF diagnosed according to the criteria of the European
Society of Cardiology [16]. Data were collected through a secure web site. The registry re-
corded demographic data, blood pressure, heart rate, body weight and height, ejection
fraction, co-morbidities, functional status, routine laboratory data, complications during
admission and prescriptions at discharge. Follow-up consisted of two visits scheduled at
3 months and at 1 year, where new hospitalizations or deaths were recorded.
The SENIORS trial randomized elderly, stable HF patients to the beta-1 selective beta
blocker nebivolol or placebo and enrolled 2128 patients ≥70 years with HF (ejection
fraction ≤35%, or having had a recent HF admission) [17]. Using the SENIORS dataset
we have published a model for the prediction of the composite of all-cause mortality or
CV hospitalization, and all-cause mortality alone [13].
2.1. Statistical analysis
In the SENIORS risk model ﬁve factors (NYHA class, prior myocardial infarction, left
atrial dimension, uric acid, and body mass index) were associated with prediction of the
composite of all-cause mortality or CV hospitalization, and all-cause mortality alone
[13]. In addition to these ﬁve variables, peripheral arterial disease, time since diagnosis
of HF, right bundle branch block, diabetesmellitus, and orthopnea featured in the compos-
ite outcome model, while creatinine, 6-min walk test, coronary artery disease CAD, and
age featured in the mortality model. Using the RICA dataset we identiﬁed the same base-
line variables used in the SENIORS risk model, except the 6 min walk test which was not
collected in RICA. Atrial dimension and uric acid were not collected in all RICA patients
and as these were important factors in the SENIORS model, patients without these vari-
ables were excluded from the analysis. Other missing data were imputed using the
mean value for all continuous variables, except for years with HF for which values of
zero were used. Missing categorical variables were imputedwith the value corresponding
to the lowest risk category.
Development of the SENIORS risk model has been described elsewhere [13] but as
RICA included an acute HF population and SENIORS an ambulatory chronic HF population
the overall risk in RICA was higher. We therefore adjusted the survival function, based on
observed annualmortality rate in the originalmodel, for the elevated risk in RICA. Patients
included in theRICA datasetwere subjected to 200 bootstrap re-sampling procedures as in
the original SENIORS model. For each sample the hazard ratio (HR) for all-causemortality
or cardiovascular hospital admission (primary outcome) and all-cause mortality (second-
ary outcome) for the RICA data was compared to a bootstrap sample of the SENIORS train-
ing dataset. The discriminatory properties of the model were tested by estimating the
Kaplan–Meier survival curves for tertiles of risk score. The log-rank test was then used
to see if the three curves were different from one another. For each tertile of baseline
risk, estimates of observed and predicted outcome event rates were made. Utility of the
model was also assessed using the c statistic [18]. All analysis was performed using
STATA (StataCorp, TX, USA), and a p-value of 0.05 was considered statistically signiﬁcant.
3. Results
We included 926 patients from RICA out of a possible 1368 who had
clean one year follow-up data as of January 30th 2013. Four hundred
and forty two patients were excluded due to missing information on
atrial dimension and uric acid but baseline characteristics of patients
who lacked these variables were similar to those patients who did not.
Mean age in RICA was 78 years compared to 76 years in SENIORS, but
RICA included a higher proportion of women, diabetes, chronic obstruc-
tive pulmonary disease, atrial ﬁbrillation (AF) and peripheral arterial
disease. Mean baseline EF was higher in RICA compared to SENIORS
(51% versus 36% respectively). Table 1 shows baseline characteristics
of RICA and SENIORS patients.
3.1. Follow-up
During one year follow-up 295 patients (31.9%) had a death or car-
diovascular hospital admission and 181 patients (19.5%) died in RICA
compared to 21.9 and 9.3% in SENIORS respectively (p b 0.001) for
comparison of both outcomes betweenRICA and SENIORS. Distributions
of risk for the primary outcome and all-cause mortality are shown in
Fig. 1A and B.
The risk model provided good discrimination for the primary out-
come and all-cause mortality for tertiles of baseline risk as shown by
Kaplan Meier curves in Fig. 2A and B.The observed versus predicted rates for the primary and secondary
outcomes are shown in Fig. 3A and B. Both observed and predicted
rates show a reliable gradient of risk. For the primary outcome of
death/CV hospital admission at one year observed/predicted rates (%)
were 34/24, 45/41 and 57/67 from lowest to highest tertile. Thus there
was an apparent underestimation of risk in the lower tertile, good
agreement in the middle tertile and some overestimation in the upper
tertile.
The c statistic for this outcome was 0.60. For all-cause mortality ob-
served/predicted rates (%) were 13/16, 32/38 and 44/70 from lowest to
highest tertile respectively. There appeared to be good agreement for
the lower and middle tertiles but an overestimation of risk in the
upper tertile with a c statistic of 0.66.
Similar results were obtained for the primary (death/CV hospital
admission) and secondary (all-cause mortality) endpoints in patients
with LVEF≥ 50%, and in those without a history of prior hospitalization
due to heart failure (data not shown).
Fig. 1. A and 1B. Distribution of risk scores and association of risk with probability of
events. Distribution of risk scores for (A) all-causemortality or cardiovascular hospital ad-
mission (N = 926); Mean (SD) risk score: 2.23 (0.66) and (B) all-cause mortality, and
their relation to probabilities of an event occurring over one year years (N = 925);
Mean (SD) risk score: 2.51 (1.03). Histograms represent percentage of patients with a par-
ticular risk score, and the solid line represents probability of an event over one year follow-
up period for a particular risk score.
Fig. 2. A. Kaplan–Meier curves of event rates stratiﬁed by tertiles of risk Kaplan–Meier
plots for the composite of all-cause mortality or cardiovascular hospital admission; tertile
1, lower risk; tertile 2, intermediate risk; and tertile 3, higher risk. p b 0.001, test long rank.
B. Kaplan–Meier curves of event rates stratiﬁed by tertiles of risk Kaplan–Meier plots for
all-cause mortality; tertile 1, lower risk; tertile 2, intermediate risk; and tertile 3, higher
risk. p b 0.001, test long rank.
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Our analysis has applied a risk model derived from a clinical trial
of elderly HF patients to a “real world” observational registry of acute
HF admissions, in both cases without restriction by left ventricular
ejection fraction. We found that the model was a reliable tool for
risk stratiﬁcation (determining if patients were at lower or higher
risk) but there was variability in estimating absolute risk. There
was moderate correlation for predicting death/CV hospital admis-
sion (c statistic = 0.60) but this appeared to be better for all-cause
mortality (c = 0.66). Our model is one of the few to focus on elderly
HF patients including those with preserved ejection fraction. When
restricting the analysis to those with ejection fraction ≥ 50% and no
evidence of prior HF we found a similar utility to the whole cohort
supporting the wide applicability of this risk model. There are sever-
al explanations for differences between predicted and observed rates
including
– variables that could be relevant to acute heart failurewhich have not
been included in the original SENIORS model
– potential that a single model cannot be applied to acute and chronic
HF populations– inherent weaknesses in the model that limit its applicability across
widely different populations as it was derived from a selected clini-
cal trial population.
Our study simpliﬁes the SENIORS riskmodel in elderly patients using
only 8 variables (NYHA class, priorMI, LA dimension, uric acid, and BMI,
peripheral arterial disease, right bundle branch block and diabetes
mellitus) in the death/CV hospital admission model, and 7 variables
(NYHA class, prior MI, LA dimension, uric acid, and BMI, creatinine
and age) in the mortality model. These variables are commonly mea-
sured in the clinical practice in elderly HF patients which could make
the model more applicable in routine clinical care.
Risk models are helpful to determine prognosis in patients with
complex conditions. One of themain strategies with elderly HF patients
is to maintain a good quality of life and avoid hospital admissions and
our riskmodel could identify thosewho requiremore intense treatment
and follow-up or in some cases those that require supportive or pallia-
tive care. However clinical risk prediction in these patients can be chal-
lenging due to the presence of co-morbidities and therefore a speciﬁc
risk model can provide additional useful information on top of clinical
assessment.
Fig. 3. A. Probability of a primary outcome event (death or cardiovascular hospitalization)
observed/expected at 1 year in each tertile of baseline risk. B. Probability of all cause mor-
tality observed/expected at 1 year in each tertile of baseline risk.
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of the SEATTLE riskmodel, but this did not focus on elderly patients [11].
There is a need to validate riskmodels in awide range of HF patients in-
cluding the elderly and those with diabetes [19–21]. A further valida-
tion study applying the SEATTLE risk model to HF patients N80 years
showed a large underestimation of risk and the authors concluded
that further work was needed to validate risk models in elderly HF pa-
tients [21].
Pocock and colleagues [22] have reported ameta-analysis of individ-
ual patient level data on 39,372 patients with HF enrolled into 30 cohort
studies. The authors identiﬁed 13 individual predictors of mortality
(age, lower EF, NYHA class, serum creatinine, diabetes, not prescribed
beta-blocker, lower systolic blood pressure, lower body mass, time
since diagnosis, current smoker, chronic obstructive pulmonary disease,
male gender, and not prescribed ACE-inhibitor or angiotensin-receptor
blockers). Age appeared to be more predictive of mortality in HF with
preserved ejection fraction. The mean age of survivors in the meta-
analysis was 64 years (and 72 years for those that died) indicating
that most patients in these studies were younger than those included
in our analysis. Age did not feature as a predictor in our ﬁnal model
probably because we included an elderly population.
A systematic review of predictive models for patients with HF pro-
vides important insights into strengths and weaknesses of those heart
failure risk models that have undergone external validation analyses
[23]. Their conclusions are that “thesemodels showed inconsistent per-
formance including the Heart Failure Survival Score [24] and SeattleHeart Failure Model which demonstrated modest discrimination and
questionable calibration. A new model derived from contemporary pa-
tient cohorts may be required for improved prognostic performance”.
One key problem is that many models are derived from clinical trials
or populations with limited generalizability which is a criticism that
can be applied to our analysis. A risk model has also been developed
in 4128 patients in the I-PRESERVE trial (preserved EF, mean age 72
years). NT-ProBNP, age, diabetes, previous hospitalization and left ven-
tricular EF were the strongest independent prognostic factors [25]. This
study has younger patients than our analysis, was restricted to patients
with preserved EF and has not been externally validated yet. Eapen et al.
report a 30 day risk stratiﬁcation model in 33,000 patients with mean
age 80 years hospitalized with both impaired and preserved ejection
fraction using routinely available data [26]. The 30-day mortality
model demonstrated good discrimination with a c-index of 0.75 while
the mortality/rehospitalization model demonstrated more modest
discrimination with a c-index of 0.62 which is similar to our results
even though their model is an “internal” validation in contrast to ours
which is an external validation.
There are some limitations to our study. The risk model shows vari-
ability in estimates of observed versus predicted risk and although some
of this would be expected the upper tertile of all-cause mortality shows
a clear discrepancy. However there does not appear to be an accepted
standard for discrepancies between observed and predicted risks and
this could be a subject for future discussion in professional societies.
Also our model cannot be readily applied to the clinical situation as
the calculation is complex but this limitation is common to most risk
models in HF. One area for further investigation is why the different
HF risk models include different variables. This may be in part be due
to inclusion of different variables in the study database for example
some models include NT-proBNP but this variable is not routinely col-
lected in many studies. In our model we believe that uric acid and left
atrial dimension are two key components to improve the approach to
the prognosis of elderly HF patients.
5. Conclusion
Our ﬁndings show that the SENIORS risk model was a reliable tool
for risk stratiﬁcation of elderly HF patients in a “real world” registry,
but predicted versus observed risk showed some variability. This
model provides a useful basis for clinical risk prediction but further
work is needed to develop a reliable risk tool for elderly patients with
acute heart failure.
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Epelde F, Formiga F, González A, Guisado ME, Lebrón JM, Llacer P,
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